Our small-molecule programme, led by S-pindolol benzoate (ACM-001.1), consists of multi-action agents that affect more than one pathway critical to the development of cachexia. It focuses on a class of agents that have multiple pharmacological effects that result in:

•  Reduction in catabolism and the expenditure of energy

•  Increase in anabolism

•  Increase of appetite and reduced fatigue

Ultimately, this treatment method has the potential to improve patient quality of life and may improve overall rates of survival in patients impacted by cachexia.